Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Avalo Therapeutics (AVTX) over the last 10 years, with Q3 2025 value amounting to -$13.3 million.

  • Avalo Therapeutics' Cash from Investing Activities changed N/A to -$13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.1 million, marking a year-over-year decrease of 2372949.44%. This contributed to the annual value of $356000.0 for FY2024, which is 36766.92% up from last year.
  • Latest data reveals that Avalo Therapeutics reported Cash from Investing Activities of -$13.3 million as of Q3 2025.
  • In the past 5 years, Avalo Therapeutics' Cash from Investing Activities registered a high of $356000.0 during Q1 2024, and its lowest value of -$70.9 million during Q2 2025.
  • Over the past 5 years, Avalo Therapeutics' median Cash from Investing Activities value was -$56000.0 (recorded in 2022), while the average stood at -$9.3 million.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first tumbled by 2857.14% in 2021, then surged by 36766.92% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Cash from Investing Activities stood at -$11000.0 in 2021, then crashed by 254.55% to -$39000.0 in 2022, then crashed by 241.03% to -$133000.0 in 2023, then soared by 367.67% to $356000.0 in 2024, then plummeted by 3825.0% to -$13.3 million in 2025.
  • Its Cash from Investing Activities stands at -$13.3 million for Q3 2025, versus -$70.9 million for Q2 2025 and $356000.0 for Q1 2024.